CrushSCI.com
78.2Average days
55Median days
16Fastest days
314Longest days
3242025 publications

Paper Review Records

All Paper Review Records

12 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

314 days

Illuminating the future: energy-based focal therapies for prostate cancer

Authors
Anirban Goutam Mukherjee; Abilash Valsala GopalakrishnanShow moreShow less
Affiliations
1. Department of Biotechnology, School of Sciences and Humanities, SR University, Warangal, India; 2. Department of Biomedical Sciences, School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, IndiaShow moreShow less
Source PDF DOI Publisher page
46 days

Robotic-assisted versus open radical nephrectomy with inferior vena cava thrombectomy for renal cell carcinoma: a systematic review and meta-analysis of perioperative outcomes and oncological endpoints

Authors
Diego Villalobos-Almanza; Alfredo Salazar-Monroy; Daniel Olvera‐PosadaShow moreShow less
Affiliations
1. Hospital Zambrano HellionShow moreShow less
Source PDF DOI Publisher page
66 days

MiR-590 suppresses the progression of non-small cell lung cancer by regulating YAP1 and Wnt/β-catenin signaling

Authors
X. Hao; A. SuShow moreShow less
Affiliations
1. Department of Internal Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China; 2. General Department, Bejing Chaoyang District Sanhuan Cancer Hospital, Beijing, ChinaShow moreShow less
Source PDF DOI Publisher page
70 days

Human umbilical cord mesenchymal stem cell-derived exosomes carrying hsa-miRNA-128-3p suppress pancreatic ductal cell carcinoma by inhibiting Galectin-3

Authors
X. Xie; J. Ji; X. Chen; W. Xu; H. Chen; S. Zhu; J. Wu; Y. Wu; Y. Sun; W. Sai; Z. Liu; M. Xiao; B. BaoShow moreShow less
Affiliations
1. Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, China; 2. Office of Infection Management, Affiliated Hospital of Nantong University, Nantong, China; 3. Department of Gastroenterology, Second People’s Hospital of Nantong, Nantong, China; 4. Medical School of Nantong University Oral Medicine, Nantong, China; 5. Blood Center of Jiangsu Province, Nanjing, China; 6. Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, ChinaShow moreShow less
Source PDF DOI Publisher page
46 days

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

Authors
P. García-Alfonso; M. Saiz-Rodríguez; R. Mondéjar; J. Salazar; D. Páez; A. M. Borobia; M. J. Safont; I. García-García; R. Colomer; X. García-González; M. J. Herrero; L. A. López-Fernández; F. Abad-SantosShow moreShow less
Affiliations
1. Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Sociedad Española de Oncología Médica (SEOM), Madrid, Spain; 2. Research Unit, Fundación Burgos por la Investigación de la Salud (FBIS), Hospital Universitario de Burgos, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Burgos, Spain; 3. Medical Oncology Service, Hospital Universitario de la Princesa, Sociedad Española de Oncología Médica (SEOM), Madrid, Spain; 4. Research Institute of Hospital de la Santa Creu I Sant Pau, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Barcelona, Spain; 5. Medical Oncology Department, Hospital de la Santa Creu I Sant Pau, Sociedad Española de Oncología Médica (SEOM), Barcelona, España; 6. Clinical Pharmacology Service, Hospital Universitario La Paz, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Madrid, Spain; 7. Medical Oncology Service, Consorcio Hospital General Universitario de Valencia, Universidad de Valencia, CIBERONC, Sociedad Española de Oncología Médica (SEOM), Valencia, Spain; 8. Medical Oncology Service, Hospital Universitario de La Princesa y Cátedra de Medicina Personalizada de Precisión de la Universidad Autónoma de Madrid (UAM), Sociedad Española de Oncología Médica (SEOM), Madrid, Spain; 9. Hospital Pharmacy Service, Hospital General Universitario Gregorio Marañón, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Madrid, Spain; 10. Pharmacogenetics Platform, IIS La Fe-Hospital La Fe and Pharmacology Department, Universidad de Valencia, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Valencia, Spain; 11. Clinical Pharmacology Service, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Madrid, SpainShow moreShow less
Source PDF DOI Publisher page
56 days

Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer

Authors
H. Kim; Y. J. Heo; Y. A. Cho; S. Y. Kang; S. Ahn; K. -M. KimShow moreShow less
Affiliations
1. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; 2. The Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; 3. Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of KoreaShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Clinical & Translational Oncology take to review a manuscript?

As of 2026-11-19, CrushSCI has 12 complete review records for Clinical & Translational Oncology. The fastest paper went from submission to acceptance in 16 days (Future care for long-term cancer survivors: towards a new model, received 2021-07-26, accepted 2021-08-11); the slowest took 314 days. The average is 78.2 days and the median is 55 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.